The DOI matches its Crossref record; 159 of the 162 references it cites were found in a registry or an index.
The iron metabolism of neoplastic cells: alterations that facilitate proliferation?
Abstract
For many years it has been known that neoplastic cells express high levels of the transferrin receptor 1 (TfR1) and internalize iron (Fe) from transferrin (Tf) at a tremendous rate. Considering the high requirement of neoplastic cells for Fe, understanding its metabolism is vital in terms of devising potential new therapies. Apart from TfR1, a number of molecules have been identified that may have roles in Fe metabolism and cellular proliferation. These molecules include transferrin (Tf), the oestrogen-inducible transferrin receptor-like protein, transferrin receptor 2 (TfR2), melanotransferrin (MTf), ceruloplasmin, and ferritin. In the present review these latter molecules are discussed in terms of their potential functions in tumour cell Fe metabolism and proliferation. Further studies are essential to determine the specific roles of these proteins in the pathogenesis of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The malignant cancer phenotype is often found in association with a deregulated iron homeostasis, particularly the expression of iron-regulated genes that fuel their higher metabolic iron demands needed for division, growth, and survival [10].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [10]
Citations
Cites
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-399 · Cited by 3,664
Cloning and characterization of a mammalian proton-coupled metal-ion transporter
Gunshin, H., Mackenzie, B., Berger, U. V., Gunshin, Y., Romero, M. F., Boron, W. F., Nussberger, S., Gollan, J. L., & Hediger, M. A. (1997) · Nature · doi:10.1038/41343 · Cited by 3,166
The ferritins: molecular properties, iron storage function and cellular regulation
Harrison, P. M., & Arosio, P. (1996) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(96)00022-9 · Cited by 2,667
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., VARMUS, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,261
Nitric oxide: A cytotoxic activated macrophage effector molecule
Hibbs, J. B., Taintor, R. R., Vavrin, Z., & Rachlin, E. M. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80015-9 · Cited by 2,034
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
Schwab, M., Alitalo, K. K., Klempnauer, K.-H., VARMUS, H. E., Bishop, J. M., Gilbert, F., Brodeur, G. M., Goldstein, M. N., & Trent, J. M. (1983) · Nature · doi:10.1038/305245a0 · Cited by 1,405
Hentze, M. W., & Kühn, L. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8175 · Cited by 1,292
Iron Transport and Storage Proteins
Aisen, P., & Listowsky, I. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.002041 · Cited by 1,179
Thelander, L., & Reichard, P. A. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001025 · Cited by 1,160
Research works printed but not linked: 2
- Frantz CN, Iyer J, Frick KK, Eskenazi AE, Derg PE. Iron and N-myc expression in neuroblastoma. Proceedings of the Neuroblastoma Research Meeting, Philadelphia, USA; 1993.
- Frantz CN, Eskenazi AE, Overman D. Iron chelation cancer therapy for neuroblastoma. Proceedings of the International Conference on Bioiron, Asheville, North Carolina, USA; 1995. p. 195.
Cited by
Sorted by citations
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,035
“Instead, it may help in the rapid proliferation of tumor cells and also act as an iron scavenger at the cell surface to prevent lipid peroxidation (Kwok and Richardson, 2002).”
BackgroundThe Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
“This is reflected by the fact that tumor cells have higher numbers of Tf receptors on their cell surface, mediating a high rate of iron uptake (Richardson and Baker, 1990, 1992; Trinder et al., 1996; for reviews, see Kwok and Richardson, 2002; Le and Richardson, 2002).”
BackgroundSelf-citationDaniels‐Wells, T. R., Delgado, T., Rodríguez, J. A., Helguera, G. F., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.010 · Cited by 646
The Molecular Mechanism of Action of Artemisinin—The Debate Continues
O’Neill, P. M., Barton, V., & Ward, S. A. (2010) · Molecules · doi:10.3390/molecules15031705 · Cited by 618
“Selective activation of artemisinin by tumor cells has led to proposal of an iron dependent hypothesis due to the understanding that tumor cells maintain a high intracellular iron concentration to sustain continued proliferation in addition to an increased capacity to synthesize heme [43].”
BackgroundRedox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Metadata
- Authors
- Kwok, J. C., & Richardson, D. R.
- Affiliations
- The Heart Research Institute (AU)
- Corresponding author
- Richardson, Des R.
- ORCID
- Richardson, Des R.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2002-04
- Volume
- 42
- Issue
- 1
- Pages
- 65-78
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W2049332203
- Cited by
- 215
- References
- 162
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 14 · 2023: 15 · 2022: 5 · 2021: 11 · 2020: 10 · 2019: 8 · 2018: 6 · 2017: 13 · 2016: 9 · 2015: 13 · 2014: 10 · 2013: 18 · 2012: 9
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Reviews in Oncology/Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- iron metabolism, neoplastic cells, transferrin receptor 1, transferrin receptor 2, transferrin, melanotransferrin, ceruloplasmin, ferritin, tumor cell proliferation, carcinogenesis, iron transport
- MeSH terms
- Animals, Antigens, Neoplasm, Biological Transport, Cell Division, Ceruloplasmin, Endocytosis, Estrogens, Ferritins, Humans, Iron, Neoplasm Proteins, Neoplasms, Receptors, Transferrin, Transferrin, Nonheme Iron Proteins, Melanoma-Specific Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
